Viking Therapeutics Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $47.39, denoting a -0.86% change from the preceding trading day.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.43, marking a -0.41% move from the previous day.
The Best Biotech Stock to Invest $1,000 in Right Now
Viking Therapeutics has a few promising drug programs near maturity. It will have to ward off tough competitors to succeed.
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It
Viking Therapeutics has the potential to be a great growth stock. The company, however, faces a lot of competition in the GLP-1 drug market.
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $52.10, denoting a -0.69% change from the preceding trading day.
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
This High-Flying Stock Just Announced More Good News: Time to Buy?
Viking Therapeutics just reported (more) positive phase 2 clinical trial results. Though the company's shares dropped, interested investors shouldn't worry.
Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $55.99, signifying a +1.78% move from its prior day's close.
Is Viking Therapeutics Stock a Buy on the Dip?
Viking Therapeutics stock took a hit this week in response to a clinical update for its midstage liver disease drug. This pullback seems unwarranted, given the company's pivot to weight loss.
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.
Here's Why Viking Therapeutics, Inc. (VKTX) Gained But Lagged the Market Today
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.26, representing a +0.78% change from its previous close.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
